This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Edgewise Therapeutics, Inc.. Active years: 2025-2026.
Company Filing History:
Years Active: 2025-2026
Title: Michael Mark DuVall: Innovator in Cardiac Treatment
Introduction
Michael Mark DuVall is a prominent inventor based in Vancouver, WA (US). He has made significant contributions to the field of cardiac treatment through his innovative research and development of new compounds. With a total of 2 patents, DuVall is recognized for his work in addressing serious cardiac conditions.
Latest Patents
DuVall's latest patents include the development of quinazolinone dione compounds and their uses for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Additionally, he has worked on 1,4-dihydroquinazolinone compounds, which also target similar cardiac conditions. These advancements showcase his commitment to improving patient outcomes in the field of cardiology.
Career Highlights
DuVall is currently associated with Edgewise Therapeutics, Inc., where he continues to push the boundaries of cardiac treatment. His work has been instrumental in developing therapies that address critical heart conditions, making a lasting impact on the medical community.
Collaborations
Some of his notable coworkers include Kevin Koch and Stephen T Schlachter, who collaborate with him in advancing cardiac treatment solutions.
Conclusion
Michael Mark DuVall's innovative work in developing compounds for cardiac treatment highlights his dedication to improving healthcare. His contributions are paving the way for new therapies that can significantly enhance the quality of life for patients with heart conditions.